Design, Synthesis and Pharmacological Evaluation of Novel 4-Phenoxyquinoline Derivatives as VEGFR2 Kinase Inhibitors for Tumor Treatment

Abstract

Vascular endothelial growth factor 2 (VEGFR2) plays a vital role in regulating of tumor metastasis and angiogenesis, which has emerged as one of the effective targets for clinical tumor therapy. Herein, a series of novel facilely accessible 4-phenoxyquinoline derivatives was prepared and assessed for their antitumor activity against three human tumor cell lines (SGC-7901, HepG2 and A549). Among these compounds, 6a, 6b and 6c show strong antitumor activity on HepG2 cells [the drug concentration of eliminating half of tumor cells (IC₅₀)=9.33, 1.84, 8.54 μmol/L]. Notably, compound 6b shows potent selective inhibitory activity against VEGFR2 kinase with an IC50 value of 4.66 nmol/L. The excellent anti-angiogenesis capability of compound 6b was confirmed by tube formation and chick chorioallantoic membrane (CAM) assay. In vivo studies confirmed that compound 6b was able to inhibit tumor growth in HepG2 xenografts of BALB/c nude mice without obvious side or toxic effects. The results demonstrated that compound 6b exhibited remarkable anti-angiogenesis and tumor growth inhibitory effects with less toxicity in vitro and in vivo models. These findings highlighted the potential of compound 6b as a promising VEGFR2 kinase inhibitor for the development of antitumor drugs.

Keywords

ar endothelial growth factor 2 (VEGFR2) / 4-Phenoxyquinoline / Inhibitor / Anti-tumor / Angiogenesis

References

[1] HendriksW, BourgonjeA, LeendersW, PulidoR Molecules, 2018, 23: 395

[2] JiaoQ, BiL, RenY, SongS, WangQ Mol. Cancer., 2018, 17: 36

[3] BhanumathyK, BalagopalA, VizeacoumarF S, VizeacoumarF J, FreywaldA, GiambraV Cancers (Basel)., 2021, 13: 184

[4] PattersonH, NibbsR, McInnesI, SiebertS Clin. Exp. Immunol., 2014, 176: 1

[5] AhnR, Ursini-SiegelJ Int. J. Mol. Sci., 2021, 22: 2608

[6] EbrahimiN, FardiE, GhaderiH, PalizdarS, KhorramR, VafadarR, GhanaatianV, Rezaei-TazangiF, BaziyarP, AhmadiA, HamblinM R, ArefA R Cell Mol. Life Sci., 2023, 80: 104

[7] JinH, DanH-G, RaoG-W Heterocyclic Communications, 2018, 24: 1

[8] YamaokaT, KusumotoS, AndoK, OhbaM, OhmoriT Int. J. Mol. Sci., 2018, 19: 3491

[9] LiuY, LiY, WangY, LinC, ZhangD, ChenJ, OuyangL, WuF, ZhangJ, ChenL Journal of Hematology & Oncology, 2022, 15: 89

[10] QinS, LiA, YiM, YuS, ZhangM, WuK J. Hematol Oncol., 2019, 12: 27

[11] ShaikF, CuthbertG A, Homer-VanniasinkamS, MuenchS P, PonnambalamS, HarrisonM A Biomolecules, 2020, 10: 1673

[12] ChenJ-C, ChangY-W, HongC-C, YuY-H, SuJ-L Int. J. Mol. Sci., 2012, 14: 88

[13] MalekanM, EbrahimzadehM A Curr. Top. Med. Chem., 2022, 22: 891

[14] AdelM, SeryaR A T, LasheenD S, AbouzidK A M Bioorg. Chem., 2018, 81: 612

[15] ChengK, LiuC-F, RaoG-W Curr. Med. Chem., 2021, 28: 2540

[16] KaufmanN E M, DhingraS, JoisS D Molecules, 2021, 26: 1076

[17] FalconB L, ChintharlapalliS, UhlikM T, PytowskiB Pharmacol Ther., 2016, 164: 204

[18] MabetaP, SteenkampV Int. J. Mol. Sci., 2022, 23: 15585

[19] Ntanasis-StathopoulosI, FotopoulosG, TzanninisI-G, KotteasEA Cancer Invest., 2016, 34: 313

[20] FarghalyT A, Al-HasaniW A, AbdulwahabH G Expert Opin. Ther. Pat., 2021, 31: 989

[21] WangX, BoveA M, SimoneG, MaB Front Cell Dev. Biol., 2020, 8: 599281

[22] ZhongL, LiY, XiongL, WangW, WuM, YuanT, YangW, TianC, MiaoZ, WangT, YangS Sig. Transduct Target Ther., 2021, 6: 1

[23] AutiP S, GeorgeG, PaulA T RSC Adv., 2020, 10: 41353

[24] HameedA, Al-RashidaM, UroosM, AliS A, ArshiaI M, KhanK M Expert Opin. Ther. Pat., 2018, 28: 281

[25] JafariE, KhajoueiM R, HassanzadehF, HakimelahiG H, KhodarahmiG A Research in Pharmaceutical Sciences, 2016, 11: 1

[26] PengF-W, LiuD-K, ZhangQ-W, XuY-G, ShiL Expert Opin. Ther. Pat., 2017, 27: 987

[27] DasR, MehtaD K, DhanawatM Anticancer Agents Med. Chem., 2021, 21: 1350

[28] MartoranaA, La MonicaG, LauriaA Molecules, 2020, 25: 4279

[29] GellerG, LaskinJ, CheungW Y, HoC Thyroid Res., 2017, 10: 6

[30] XiaoZ, ChuC, ZhouL, ZhouZ, ZhangQ, YangF, YangZ, ZhengP, XuS, ZhuW Bioorg. Med. Chem., 2020, 28: 115669

[31] MomenyM, AlishahiZ, EyvaniH, EsmaeiliF, ZaghalA, GhaffariP, Tavakkoly-BazzazJ, AlimoghaddamK, GhavamzadehA, GhaffariSH Cell Oncol. (Dordr.), 2020, 43: 81

[32] OrbegosoC, MarquinaG, GeorgeA, BanerjeeS Expert Opin. Pharmacother., 2017, 18: 1637

[33] ZhaoB, LeiF, WangC, ZhangB, YangZ, LiW, ZhuW, XuS Molecules, 2018, 23: 1553

[34] LiuD, LuanT, KongJ, ZhangY, WangH-F Molecules, 2015, 21: E21

[35] LiuD, XueA, LiuZ, ZhangY, PengP, WangH Letters in Drug Design & Discovery., 2019, 16: 663

[36] WeiH, DuanY, GouW, CuiJ, NingH, LiD, QinY, LiuQ, LiY Eur. J. Med Chem., 2019, 181: 111552

[37] BerrinoE, MicheletB, Martin-MingotA, CartaF, SupuranC T, ThibaudeauS Angewandte Chemie International Edition, 2021, 60: 23068

[38] HeveyR Chemistry, 2021, 27: 2240

[39] RichardsonP Expert Opin. Drug Discov., 2021, 16: 1261

[40] PengS, WangY, PengH, ChenD, ShenS, PengB, ChenM, LencioniR, KuangM Hepatology, 2014, 60: 1264

[41] GoelS, ChenF, HongH, ValdovinosH F, HernandezR, ShiS, BarnhartT E, CaiW ACS Appl. Mater. Interfaces, 2014, 6: 21677

[42] LiJ, WuY, WangD, ZouL, FuC, ZhangJ, LeungG P H Pharmacol Res., 2019, 146: 104313

[43] FerraraN, GerberH-P, LeCouterJ Nat. Med., 2003, 9: 669

[44] OlssonA-K, DimbergA, KreugerJ, Claesson-WelshL Nat. Rev. Mol. Cell Biol., 2006, 7: 359

RIGHTS & PERMISSIONS

Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH